Publications Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease Citation Al Draiweesh S, Ma C, Alkhattabi M, McDonald C, Nguyen TM, Beaton M, Chande N, Colquhoun P, Feagan BG, Gregor JC, Khanna R, Marotta P, Ponich T, Quan D, Qumosani K, Sandhu A, Sey M, Skaro A, Teriaky A, Wilson A, Yan B, Brahmania M, Jairath V. Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020 May 12;26(6):949-959. doi: 10.1093/ibd/izz244. PMID: 31665288. Abstract Background: Patients with inflammatory bowel disease (IBD) post-liver transplant (LT) may have bowel inflammation requiring biologic therapy. We aimed to evaluate the safety of combination biologic and antirejection therapy in IBD patients after LT from a tertiary center case series and an updated literature review. Tags Adverse Effects, Biological Products, Cholangitis, Clostridium Infections, Complications, Crohn's Disease, Etiology, IBD, Immunosuppression Therapy, Inflammatory Bowel Disease, Liver Transplant, Liver Transplantation, Sclerosing, therapeutic use, Ulcerative Colitis Read More
